| 000 | 01921 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516105259.0 | ||
| 264 | 0 | _c20130117 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a1556-1380 | ||
| 024 | 7 |
_a10.1097/JTO.0b013e318260dfb9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFennell, Dean A | |
| 245 | 0 | 0 |
_aPhase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. _h[electronic resource] |
| 260 |
_bJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer _cSep 2012 |
||
| 300 |
_a1466-70 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBoronic Acids _xtherapeutic use |
| 650 | 0 | 4 | _aBortezomib |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunoenzyme Techniques |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMesothelioma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPleural Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-bcl-2 _xmetabolism |
| 650 | 0 | 4 |
_aPyrazines _xtherapeutic use |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aMcDowell, Cliona | |
| 700 | 1 | _aBusacca, Sara | |
| 700 | 1 | _aWebb, Glen | |
| 700 | 1 | _aMoulton, Brian | |
| 700 | 1 | _aCakana, Andrew | |
| 700 | 1 | _aO'Byrne, Kenneth J | |
| 700 | 1 | _aMeerbeeck, Jan V | |
| 700 | 1 | _aDonnellan, Paul | |
| 700 | 1 | _aMcCaffrey, John | |
| 700 | 1 | _aBaas, Paul | |
| 773 | 0 |
_tJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer _gvol. 7 _gno. 9 _gp. 1466-70 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/JTO.0b013e318260dfb9 _zAvailable from publisher's website |
| 999 |
_c22026944 _d22026944 |
||